What is Claimed:

1. A compound of Formula (I):



(I)

wherein:

Z^1 and Z^2 are independently $-NR^3-$ (wherein R^3 is hydrogen or alkyl) or -O-;

R^1 and R^2 are independently substituted alkyl, substituted aryl, heteroaryl, or substituted heteroaryl provided that at least one of R^1 and R^2 is a group that can form a pharmaceutically acceptable acid addition salt;

R^3 is hydrogen, alkyl or R^3 and R^1 or R^2 together with the atoms to which they are attached form a heterocyclic ring;

X^2 is aryl, substituted aryl, heteroaryl, substituted heteroaryl, alkenyl, alkynyl, cycloalkyl or heterocyclic;

X^1 and X^3 are independently aryl, substituted aryl, heteroaryl, substituted heteroaryl, or $-CHR^4$, wherein R^4 is natural or unnatural amino acid side chain;

or a pharmaceutically acceptable acid addition salt thereof.

2. The compound of Claim 1, wherein Z^1 and Z^2 are –NH-.

3. The compound of Claim 2, wherein X^2 is aryl, substituted aryl, heteroaryl or substituted heteroaryl.

4. The compound of Claim 2, wherein R^1 and R^2 are independently substituted alkyl groups.

5. The compound of Claim 3, wherein X^2 is an aryl, substituted aryl, heteroaryl or substituted heteroaryl moiety selected from a group consisting of the following moieties:




























wherein,

R^5 is hydrogen, alkyl or substituted alkyl;

R^6 is hydrogen, alkyl, halo or alkoxy;

R^7 is hydrogen, alkyl or halo;

R^8 is hydrogen, alkyl, substituted alkyl, alkoxy or halo;

R^9 is hydrogen, alkyl, substituted alkyl, alkoxy, nitro or halo;

R^{10} is hydrogen or alkyl;

R^{11} is hydrogen or alkyl; and,

R^{12} is hydrogen or alkyl.

6. The compound of Claim 2, wherein X^1 and X^3 are heteroaryl or substituted heteroaryl moieties independently selected from a group consisting of the following moieties:



wherein

R^{13} is hydrogen of alkyl; and,

R^{14} is hydrogen, alkyl or substituted alkyl.

7. The compound of Claim 4, wherein R^1 and R^2 are substituted alkyl moieties independently selected from a group consisting of the following moieties:



wherein

R^{15} is hydrogen, hydroxyl, alkoxyl, alkyl, cycloalkyl or R^{15} and R^{16} together with the atoms to which they are attached form a heterocyclic ring;

R^{16} is hydrogen, hydroxyl, alkyl or cycloalkyl;

R^{17}, R^{18}, R^{19} and R^{20} are independently hydrogen or alkyl;

R^{21} is hydrogen alkyl, substituted alkyl, cycloalkyl or acyl;

R^{22} is hydrogen or alkyl, or R^{22} and R^{23} together with the atoms to which they are attached form a heterocyclic ring, or R^{22} and R^{24} together with the atoms to which they are attached form a heterocyclic ring.

R^{23} is hydrogen, hydroxyl, alkyl, cycloalkyl or R^{23} and R^{24} together with the atoms to which they are attached form a heterocyclic ring;

R^{24} is hydrogen, hydroxyl or alkyl;

m is 1, 2 or 3;

n is 1, 2 or 3; and,

o is 0, 1, 2 or 3.

8. The compound of Claim 6, wherein R^{14} is an alkyl or substituted alkyl moiety, and wherein the moiety is selected from a group consisting of the following moieties:





9. The compound of Claim 5, wherein X^1 and X^3 are heteroaryl or substituted heteroaryl moieties independently selected from a group consisting of the following moieties:



wherein

R^{13} is hydrogen of alkyl;

R^{14} is hydrogen, alkyl or substituted alkyl;

and wherein R^1 and R^2 are substituted alkyl moieties independently selected from a group consisting of the following moieties:





wherein

R^{15} is hydrogen, hydroxyl, alkoxyl, alkyl, cycloalkyl or R^{15} and R^{16} together with the atoms to which they are attached form a heterocyclic ring;

R^{16} is hydrogen, hydroxyl, alkyl or cycloalkyl;

R^{17}, R^{18}, R^{19} and R^{20} are independently hydrogen or alkyl;

R^{21} is hydrogen alkyl, substituted alkyl, cycloalkyl or acyl;

R^{22} is hydrogen or alkyl, or R^{22} and R^{23} together with the atoms to which they are attached form a heterocyclic ring, or R^{22} and R^{24} together with the atoms to which they are attached form a heterocyclic ring.

R^{23} is hydrogen, hydroxyl, alkyl, cycloalkyl or R^{23} and R^{24} together with the atoms to which they are attached form a heterocyclic ring;

R^{24} is hydrogen, hydroxyl or alkyl;

m is 1, 2 or 3;

n is 1, 2 or 3; and,

o is 0, 1, 2 or 3.

10. The compound of Claim 9, wherein X^2 is



11. The compound of Claim 9, wherein X^1 and X^3 are both



12. The compound of Claim 10, wherein R^1 and R^2 are of the following structure:



wherein

o is 0;

R^{17} and R^{18} are hydrogen; and,

R^{21} is hydrogen, alkyl or acyl.

13. The compound of Claim 11, wherein R^1 and R^2 are of the following structure:



wherein

R^{15} and R^{16} are hydrogen; and,

n is 1 or 2.

14. The compound of Claim 12, wherein R^{19} and R^{20} are hydrogen, and wherein R^{21} is an alkyl group selected from a group consisting of methyl, ethyl and propyl, or an acyl moiety of the structure $-C(O)C(R^{25})(R^{26})H$,

wherein

R^{25} is a substituent selected from a group consisting of the following substituents:














or R^{25} and R^{26} together with the atom to which they are attached form a heterocyclic ring of the following structure:



and wherein R^{26} is a substituent selected from a group consisting of the following substituents: -H, $-NH_2$ and $-NHCH_3$.

15. The compound of Claim 12, wherein R^1 and R^2 are independently of one of the following structures:




wherein

R^{19} and R^{20} are independently hydrogen or alkyl; and,

R^{21} is hydrogen, alkyl or acyl.

16. The compound of Claim 13, wherein R^{14} is an alkyl or substituted alkyl moiety, and wherein the moiety is selected from a group consisting of the following moieties:





17. The compound according to Claim 14, wherein the compound is of the following structure:



18. The compound according to Claim 16, wherein the compound is of the following structure:



wherein R^{14} is hydrogen, $-CH_2CH_2CH(CH_3)_2$ or $-CH_2(C_3H_5)$, and wherein X^2 is a moiety selected from a group consisting of the following moieties:



19. A method of treating bacterial or fungal infections, wherein the method comprises administration of a therapeutically effective amount of a compound of Formula (I):



(I)

wherein:

Z^1 and Z^2 are independently $-NR^3-$ (wherein R^3 is hydrogen or alkyl) or -O-;

R^1 and R^2 are independently substituted alkyl, substituted aryl, heteroaryl, or substituted heteroaryl provided that at least one of R^1 and R^2 is a group that can form a pharmaceutically acceptable acid addition salt;

R^3 is hydrogen, alkyl or R^3 and R^1 or R^2 together with the atoms to which they are attached form a heterocyclic ring;

X^2 is aryl, substituted aryl, heteroaryl, substituted heteroaryl, alkenyl, alkynyl, cycloalkyl or heterocyclic;

X^1 and X^3 are independently aryl, substituted aryl, heteroaryl, substituted heteroaryl, or $-CHR^4$, wherein R^4 is natural or unnatural amino acid side chain;

or a pharmaceutically acceptable acid addition salt thereof.

20. A method of inhibiting topoisomerase, wherein the method comprises administration of a therapeutically effective amount of a compound of Formula (I):



(I)

wherein:

Z^1 and Z^2 are independently $-NR^3-$ (wherein R^3 is hydrogen or alkyl) or -O-;

R^1 and R^2 are independently substituted alkyl, substituted aryl, heteroaryl, or substituted heteroaryl provided that at least one of R^1 and R^2 is a group that can form a pharmaceutically acceptable acid addition salt;

R^3 is hydrogen, alkyl or R^3 and R^1 or R^2 together with the atoms to which they are attached form a heterocyclic ring;

X^2 is aryl, substituted aryl, heteroaryl, substituted heteroaryl, alkenyl, alkynyl, cycloalkyl or heterocyclic;

X^1 and X^3 are independently aryl, substituted aryl, heteroaryl, substituted heteroaryl, or $-CHR^4$, wherein R^4 is natural or unnatural amino acid side chain;

or a pharmaceutically acceptable acid addition salt thereof.

21. A method of treating bacterial infections, wherein the method comprises administration of a therapeutically effective amount of the following compound:



wherein R^{21} is hydrogen, alkyl, substituted alkyl, cycloalkyl or acyl.

22. A method of treating fungal infections, wherein the method comprises administration of a therapeutically effective amount of the following compound:



wherein R^{14} is hydrogen, $-CH_2CH_2CH(CH_3)_2$ or $-CH_2(C_3H_5)$, and wherein X^2 is a moiety selected from a group consisting of the following moieties:





wherein

R^5 is hydrogen, alkyl or substituted alkyl;

R^8 is hydrogen, alkyl, substituted alkyl, alkoxy or halo;

R^9 is hydrogen, alkyl, substituted alkyl, alkoxy, nitro or halo;

R^{10} is hydrogen or alkyl; and,

R^{11} is hydrogen or alkyl.

23. A method of treating a bacterial or fungal infection, wherein the bacterial or fungal strain is selected from a group consisting of the following strains: *c. albicans*, *a. fumigatus*, *b. cereus*, *h. influenzae* and *p. aeruginosa*.